Trials / Completed
CompletedNCT02244242
Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia
A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 493 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
Study to evaluate the symptomatic relief afforded by tamsulosin hydrochloride capsules in patients with signs and symptoms of benign prostatic hyperplasia (BPH). Additionally to provide primary care physicians experience with the use of tamsulosin hydrochloride capsules 0.4 mg daily for the treatment of BPH
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tamsulosin hydrochloride |
Timeline
- Start date
- 1998-07-01
- Primary completion
- 1999-08-01
- First posted
- 2014-09-19
- Last updated
- 2014-09-19
Source: ClinicalTrials.gov record NCT02244242. Inclusion in this directory is not an endorsement.